Abstract
At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.
| Original language | English (US) |
|---|---|
| Journal | Clinical Lung Cancer |
| Volume | 9 |
| Issue number | SUPPL. 3 |
| DOIs | |
| State | Published - Mar 2008 |
Fingerprint
Keywords
- Antimicrotubule agents
- BRCA1
- Carboplatin
- ERCC1
- Gemcitabine
- RRM1
- Xeroderma pigmentosa
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer : Current status and new directions. / Gautschi, Oliver; Mack, Philip; Davies, Angela M.; Jablons, David M.; Rosell, Rafael; Gandara, David R.
In: Clinical Lung Cancer, Vol. 9, No. SUPPL. 3, 03.2008.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer
T2 - Current status and new directions
AU - Gautschi, Oliver
AU - Mack, Philip
AU - Davies, Angela M.
AU - Jablons, David M.
AU - Rosell, Rafael
AU - Gandara, David R
PY - 2008/3
Y1 - 2008/3
N2 - At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.
AB - At present, selection of chemotherapy regimens for individual patients remains largely an empirical process. Nevertheless, developing pharmacogenomic approaches for selection of chemotherapy through predictive biomarkers now appears feasible because of improved understanding of underlying molecular mechanisms. Although diverse terminology has been applied to such pharmacogenomic approaches (individualizing, customizing, or personalizing therapy), all rely on commonly shared principles for assessing tumor- or host-related factors. Herein, we summarize emerging data regarding pharmacogenomic approaches to treatment selection for non-small-cell lung cancer, focusing primarily on biomarkers relevant to 2 important chemotherapeutic drug classes: platinum compounds and antimicrotubule agents. The results of pilot studies and the first randomized prospective trial testing this concept are described, including limitations in the clinical setting of advanced-stage disease. Methodologic and technical aspects of pharmacogenomic approaches are elucidated, recommendations for clinical application are provided, and new directions in this field are projected.
KW - Antimicrotubule agents
KW - BRCA1
KW - Carboplatin
KW - ERCC1
KW - Gemcitabine
KW - RRM1
KW - Xeroderma pigmentosa
UR - http://www.scopus.com/inward/record.url?scp=62349084806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62349084806&partnerID=8YFLogxK
U2 - 10.3816/CLC.2008.s.019
DO - 10.3816/CLC.2008.s.019
M3 - Article
VL - 9
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
IS - SUPPL. 3
ER -